| Literature DB >> 23979585 |
Sudeepta Kumar Panda1, Benedikt Wefers, Oskar Ortiz, Thomas Floss, Bettina Schmid, Christian Haass, Wolfgang Wurst, Ralf Kühn.
Abstract
Targeted mouse mutants are instrumental for the analysis of gene function in health and disease. We recently provided proof-of-principle for the fast-track mutagenesis of the mouse genome, using transcription activator-like effector nucleases (TALENs) in one-cell embryos. Here we report a routine procedure for the efficient production of disease-related knockin and knockout mutants, using improved TALEN mRNAs that include a plasmid-coded poly(A) tail (TALEN-95A), circumventing the problematic in vitro polyadenylation step. To knock out the C9orf72 gene as a model of frontotemporal lobar degeneration, TALEN-95A mutagenesis induced sequence deletions in 41% of pups derived from microinjected embryos. Using TALENs together with mutagenic oligodeoxynucleotides, we introduced amyotrophic lateral sclerosis patient-derived missense mutations in the fused in sarcoma (Fus) gene at a rate of 6.8%. For the simple identification of TALEN-induced mutants and their progeny we validate high-resolution melt analysis (HRMA) of PCR products as a sensitive and universal genotyping tool. Furthermore, HRMA of off-target sites in mutant founder mice revealed no evidence for undesired TALEN-mediated processing of related genomic sequences. The combination of TALEN-95A mRNAs for enhanced mutagenesis and of HRMA for simplified genotyping enables the accelerated, routine production of new mouse models for the study of genetic disease mechanisms.Entities:
Keywords: C9ORF72; Fus; TALENs; disease model; mouse mutant; nuclease; one-cell embryo
Mesh:
Substances:
Year: 2013 PMID: 23979585 PMCID: PMC3813858 DOI: 10.1534/genetics.113.156570
Source DB: PubMed Journal: Genetics ISSN: 0016-6731 Impact factor: 4.562